Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates.

AUTOR(ES)

Walsh, T J

RESUMO

We characterized the cerebrospinal fluid (CSF) penetration and pharmacokinetics of SCH-39304 in adult rhesus monkeys receiving a single oral dose of SCH-39304 (2.0 mg/kg of body weight). The mean CSF-to-plasma area under the curve ratio was 0.63 (+/- 0.18, standard error of the mean); maximum concentrations were 1.34 micrograms/ml (+/- 0.18) in CSF and 1.96 micrograms/ml (+/- 0.43) in plasma. The mean plasma half-life was 45.7 h (+/- 11), and mean CSF half-life was 38.7 h (+/- 3.5). The mean levels of SCH-39304 at 24 h were 1.48 micrograms/ml (+/- 0.3) in plasma and 0.96 microgram/ml (+/- 0.12) in CSF. We conclude that SCH-39304 effectively penetrates into CSF and achieves concentrations considered active against many opportunistic yeasts and that these concentrations are sustained in CSF for greater than or equal to 24 h.

Documentos Relacionados

• In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy.
• Treatment of murine pulmonary blastomycosis with SCH 39304, a new triazole antifungal agent.
• In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent.
• Penetration of Colistin into Cerebrospinal Fluid▿
• Penetration of Amoxicillin into Cerebrospinal Fluid†